DURECT CORPORATION (DRRX)
US2666055007 - Common Stock
We assign a fundamental rating of 2 out of 10 to DRRX. DRRX was compared to 198 industry peers in the Pharmaceuticals industry. DRRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DRRX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
DRRX had negative earnings in the past year.
In the past year DRRX has reported a negative cash flow from operations.
In the past 5 years DRRX always reported negative net income.
DRRX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
DRRX has a Return On Assets of -61.15%. This is in the lower half of the industry: DRRX underperforms 63.59% of its industry peers.
With a Return On Equity value of -186.91%, DRRX is not doing good in the industry: 72.31% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -61.15% | ||
| ROE | -186.91% | ||
| ROIC | N/A |
ROA(3y)-53.11%
ROA(5y)-36.81%
ROE(3y)-130.31%
ROE(5y)-96.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 80.00%, DRRX belongs to the top of the industry, outperforming 84.10% of the companies in the same industry.
DRRX's Gross Margin has declined in the last couple of years.
DRRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 80% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.72%
GM growth 5Y-2.19%
2. Health
2.1 Basic Checks
DRRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DRRX has more shares outstanding
Compared to 5 years ago, DRRX has more shares outstanding
Compared to 1 year ago, DRRX has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -19.96, we must say that DRRX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -19.96, DRRX is doing worse than 86.67% of the companies in the same industry.
DRRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -19.96 |
ROIC/WACCN/A
WACC10.48%
2.3 Liquidity
A Current Ratio of 1.28 indicates that DRRX should not have too much problems paying its short term obligations.
The Current ratio of DRRX (1.28) is worse than 78.97% of its industry peers.
A Quick Ratio of 1.20 indicates that DRRX should not have too much problems paying its short term obligations.
DRRX's Quick ratio of 1.20 is on the low side compared to the rest of the industry. DRRX is outperformed by 74.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.28 | ||
| Quick Ratio | 1.2 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 27.56% over the past year.
DRRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -55.76%.
The Revenue for DRRX have been decreasing by -10.97% on average. This is quite bad
EPS 1Y (TTM)27.56%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q78.26%
Revenue 1Y (TTM)-55.76%
Revenue growth 3Y-34.28%
Revenue growth 5Y-10.97%
Revenue growth Q2Q-19.61%
3.2 Future
The Earnings Per Share is expected to grow by 28.20% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 76.97% on average over the next years. This is a very strong growth
EPS Next Y2.21%
EPS Next 2Y-5.37%
EPS Next 3Y-7.07%
EPS Next 5Y28.2%
Revenue Next Year27.43%
Revenue Next 2Y46.88%
Revenue Next 3Y41.43%
Revenue Next 5Y76.97%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
DRRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as DRRX's earnings are expected to decrease with -7.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.37%
EPS Next 3Y-7.07%
5. Dividend
5.1 Amount
DRRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DURECT CORPORATION
NASDAQ:DRRX (5/2/2024, 1:23:58 PM)
0.94
-0.03 (-3.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap29.18M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -61.15% | ||
| ROE | -186.91% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 80% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.28 | ||
| Quick Ratio | 1.2 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)27.56%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y2.21%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-55.76%
Revenue growth 3Y-34.28%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y